|
Synonyms: AEVI-002 | AVTX-002 | CERC-002 | MDGN-002 | SAR-252067 | SAR252067 [3]
Compound class:
Antibody
Comment: Quisovalimab (AVTX-002) is a clinical stage, fully human IgG4 anti-LIGHT (TNFSF14) monoclonal antibody. It was developed for anti-inflammatory potential [3]. Quisovalimab binds to LIGHT and prevents it from interacting with its receptors on T cells [1].
As CERC-002, this agent was assessed for efficacy as a treament for COVID-19-related pneumonia and ARDS/acute lung injury, based on evidence of a pro-inflammatory effect of LIGHT on the interaction between T cells and airway smooth muscle cells [2]. |
| No information available. |
Summary of Clinical Use  |
| Quisovalimab, with the previously used codes MDGN-002 and CERC-002, is under clinical evaluation as an immunomodulator. A phase 1 study in healthy volunteers revealed that quisovalimab had a favourable safety profile, was well tolerated and no serious adverse effects were detected [3]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04412057 | Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury | Phase 2 Interventional | Cerecor Inc | ||
| NCT03169894 | Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease | Phase 1 Interventional | Cerecor Inc | ||
